Humacyte (HUMA) Revenue (2020 - 2026)
Humacyte (HUMA) posted quarterly Revenue of $495000.0 for Q1 2026, down 4.26% year-over-year from $517000.0 in Q1 2025, and up 6.0% quarter-over-quarter from $467000.0 in Q4 2025.
Humacyte (HUMA) Revenue (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Revenue for 4 consecutive years, with $495000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue fell 4.26% year-over-year to $495000.0; the TTM figure through Mar 2026 stood at $2.0 million (up 289.94% YoY), while the FY2025 annual figure was $2.0 million, changed N/A from the prior year.
- Revenue advanced to $495000.0 in Q1 2026 per HUMA's latest filing, from $467000.0 in the prior quarter.
- Across five years, Revenue topped out at $753000.0 in Q3 2025 and bottomed at $301000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | 406,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 406,000.00 |
| Mar 31, 2026 | 495,000.00 |
| Dec 31, 2025 | 467,000.00 |
| Sep 30, 2025 | 753,000.00 |
| Jun 30, 2025 | 301,000.00 |
| Mar 31, 2025 | 517,000.00 |
| Sep 30, 2021 | 241,000.00 |
| Sep 30, 2020 | 914,000.00 |